William Philip Werschler, MD
Curriculum Vitae
Spokane Dermatology Clinic 104 W 5th Ave., #330-West
Spokane, WA
Premier Clinical Research 104 West 5th Ave. Suite 320 Spokane WA 99204
Phone
Fax
(509)242-1793
(509)-242-1799
Education
1981 – 1985
1976 – 1981
99204
MD, Graduation Honors
George Washington University Medical Center
Washington, DC
BA, BS, Magna Cum Laude
Eastern Washington University
Cheney, WA
Post Graduate Education
1997
Physician Entrepreneur Program
Kellogg Graduate School of Management
Northwestern University
Evanston, IL
1988 – 1989
Chief Resident, Dermatology
George Washington University Medical Center
Washington, DC
1986 – 1988
Resident, Dermatology
George Washington University Medical Center
Washington, DC
1985 – 1986
Internship, Internal Medicine
University of Arizona
Tucson, AZ
Academic Appointments
1992 – Present
Assistant Clinical Professor in Medicine/Dermatology, University
of Washington
1989 – 1992
Clinical Instructor in Medicine/Dermatology, University of
Washington
1986 – 1989
Clinical Instructor
George Washington School of Medicine
Washington, DC
Professional Practice Experience
1989 – Present
Private Practice, Spokane Dermatology Clinic
Spokane, WA
2000 – Present
Premier Clinical Research
Spokane, WA
1987 – 1989
Consultant, HMO
George Washington University Health Plan
Washington, DC
Certification
Diplomate, National Board of Medical Examiners
Board Certified, American Board of Dermatology
Fellow, American Academy of Dermatology
Fellow, American Academy of Cosmetic Surgery
Licensure
Washington, MD00026292
Hawaii, MD 13631
New York, 238324
Arizona, 34865
California, pending
Nevada, pending
Texas, pending
Washington DC, inactive
Honors
2004
2001
1985
1985
1982 – 1993
1981
1981
Model State Award, American Academy of Dermatology
Association
Alumnus Service Award, EWU Alumni Association
Walter F. Rosenburg Award in Dermatology,
George Washington University Medical School
Graduation Honors
Kane King Honor Society,
George Washington University Medical School
Graduation Award
Levine Foundation Scholarship
George Washington University Medical School
Magna Cum Laude Graduation Honors
Eastern Washington University
US Jaycees Outstanding Young Men of America Award
Organizational Leadership
1990 – 1992
Eastern Washington University College of Science, Math and
Technology Advisory Committee
1992 – Present
Leaders Society, Dermatology Foundation; State Chairman ’94-96
1993 – 1999
Eastern Washington University Foundation Board of Directors
1997 – 1999
Washington State Medical Association, Board of Trustees
1996
President, Spokane County Medical Society
1996 – 2000
Spokane Momentum Economic Development Council
1997 – 1998
United Way of Spokane County, Board of Directors
1995 – 1996
American Cancer Society, Spokane Chapter President
1992
Leadership Spokane Graduate
1993 – 1995
Leadership Spokane, Board of Directors
2003
Lifetime Member, Annenberg Circle & Leaders Society,
Dermatology Foundation
2003 – 2004
President, American Society of Cosmetic Dermatology &
Aesthetic Surgery (ASCDAS)
2004 – 2005
President, Washington State Dermatology Association
2005
Lifetime Founding Member, Amonette Circle, Skin Cancer
Foundation
Professional Organizations
Fellow, American Academy of Dermatology
Fellow, American Academy of Cosmetic Surgery
Fellow, American Society of Dermatologic Surgery
Fellow, American Society of Laser Medicine and Surgery
Fellow, American Society of Mohs Surgery
Fellow, American Society of Cosmetic Dermatology & Aesthetic Surgery
Fellow, International Society of Dermatology Surgery
Fellow, American Academy of Anti-Aging Medicine
Member, Washington State Medical Society
Past President, Washington State Dermatology Association
Member, Past President, Spokane County Medical Society
Past President, American Society of Cosmetic Dermatology and Aesthetic
Surgery
Clinical Research
Conducts the following studies with trained and experienced full-time in-office Clinical
Research Coordinators in association with Premier Clinical Research, LLC:










Matrix, Inc: “A Double-Blind Study to Compare Safety and Efficacy of Two
Administration Regimens of 1 ml of Xxxx in Treatments of Nodular Basal Cell
Carcinoma.” (1992 – 1993)
Matrix, Inc: “A Randomized, Open-Label Dose Definition Study to Compare the
Safety and Tolerance of Six Administration Regimens of Xxxx in the Treament of
Basal Cell Carcinoma.” (1993)
Bristol-Myers Squibb, Inc: “A Multicenter, Randomized Parallel Group Study to
Assess the Effects of Xxxx on the Use of an Ultrapotent Topical Corticosteroid in
Hand Dermatitis.” (1994)
Bristol-Myers Squibb, Inc: “A Double-Blind, Multi-National Trial Comparing
Xxxx vs. Xxxx for the Treatment of Acute Localized Zoster and the Effects of
Zoster-Associated Pain in Immunocompetent Subjects.” (1995)
Matrix, Inc: “A Randomized, Controlled Study to Evaluate the Contribution of
Components in Xxxx in Patients with Basal Celll Carcinoma.” (1995)
Bayer, Inc: “Prospective, Randomized, Double-Blind, Comparison of the Safety
and Efficacy of Xxxx vs. Xxxx for the Treatment of Patients with Mild to
Moderate Acute Uncomplicated Skin and Superficial Skin Structure Infection.”
(1997 – 1998)
Galderma: “Efficacy and Safety Comparison of Xxxx vs. a Triad and a Pair of
Filters, in the Prevention of Polymouphous Light Eruption in Outdoor
Conditions.” (1999)
Allergan: “A Multicenter, Double-Blind, Randomized, Placebo-Controlled,
Parallel Study of the Safety and Efficacy of Xxxx Purified Neurotoxin Complex
in Subjects with Glabellar Lines.” (1998 – 1999)
Allergan: “A Multicenter, Open Label Study of the Safety of Xxxx Purified
Neurotoxin Complex in Subjects with Glabellar Lines.” (1999 – 2000)
Allergan: “Randomized Inter-Rater and Intra-Rater Reliability Study of
Gravimetric Measurement of Spontaneous Resting Axillary Sweat Production.”
(2000)




















Galderma: “Open Label Phase Four Study of Xxxx Quality of Life in Patients
with Moderate to Severe Melasma.”
Allergan: “Open Label Extension, Inter-Rater and Intra-Rater Reliability Study
of Gravimetric Measurement of Spontaneous Resting Axillary Sweat Production.”
(2002-2004)
GlaxoSmithKline: “A Multicenter, Study of Xxxx in patients with Mild to
Moderate Psoriasis.” (2002)
Fujisawa Healthcare Inc “ A Phase III Open Label, Safety Study Of XXX in the
Treatment of Psoriasis. (2003-2004)
Genentech, Inc. “A Phase IIIb Open Label, Multicenter Study to Evaluate the
Safety of XXXX Subcutaneously Administered XXX in Adults with Moderate to
Sever Plaque Psoriasis. (2003-2004)
Amgen Inc. “A Multicenter, open Label Prospective Study to Evaluate the
Effectiveness and Safety of XXXX in the Treatment of Subjects With Psoriasis.
(2003-2004)
Valeant Pharmaceuticals “A Two Center, Randomized Study Comparing the
Safety and Efficacy of XXXX in the Treatment of Actinic Keratosis. (2003-2004)
Dermik Laboratories “ A Single Center, Single Blind 3 Arm Study of the Safety
and Efficacy of XXX in Combination with XXX verses XXX verses XXX in the
Treatment and Prevention of Recurrence of Actinic Keratoses. (2003-2004)
Dermik Laboratories “A Open Label 18 Month Safety Study of XXX For the
Treatment of Actinic Keratoses. (2003-2004)
Galderma Laboratories LLP “A Community Based Trial of XXX in the Treatment
of Rosascea. (2004)
Dermik Laboratories “ A Randomized Study of the Safety and Effectiveness of
XXX verses XXX Implant in the Treatment of Nasal Labial Fold Wrinkles.
Genentech. “A Multi-Center, open Label Prospective Study to Evaluate the
Effectiveness and Safety of XXXX in the Treatment of Subjects with Psoriasis.
(2004-Present)
Allergan “Patient Reported Outcomes in Subjects Receiving XXX for Treatment
of Moderate Glabellar Rytids.” (2005)
Neostrata “Evaluation of the Safety and Efficacy of a Series of Superficial
Chemical Peels.” (2005)
Dermik Laboratories “A Pilot Multi-Center, Patient Preference Study Comparing
Two XXX/XXX Gels for treatment of Acne.” (2005)
Graceway Pharmaceuticals “ Open Lable Safety and Pharmacokinetic Study of
XXX for One , Two , or Three Treatment Cycles to Surface Areas Greater then 25
square centimeters with Actinic Keratosis. (2005-2007)
Allergan “ A Double Blind Dose Comparison of the Safety ant Efficacy of XXX
in the treatment of Female Subjects with Moderate or Severe Glabellar Rhytids.
(2006)
Galderma Laboratories “A Multi-Center, Randomized, Double Blind, ParallelGroup Study to Demonstrate the Efficacy and Safety of XXX In Subjects with
Acne Vulgaris” (2006-2007)
Peplin “A multi-center, randomized, double-blind, double dummy, vehicle –
controlled sequential cohort study to determine the safety of XXX in patients with
actinic keratoses”(2006-2007)
Allergan “Comparative Effectiveness and Safety of XXXX in Lip AugmentationPilot Study (2007)


CollaGenex “ A Multi-Center Randomized, Double-Blind, Active-Control
Clinical Trial to Determine the Effects of XXXX in Patients with Moderate to
Severe Rosacea (2007)
Johnson & Johnson “The Pump Study” An Open Label, Community Based, Phase
Four Study to assess Facial Acne Improvement with the use of XXXX 2007
Editorial Boards
1997 – 1999
Progressive Clinical Insights, Editorial Board, Contributing
Editor, Paramedical Consultants, Inc.
1999 – Present
Skin& Aging, Editorial Advisory Board, Contributing Editior,
HMP Communications, Inc.
2001 – Present
Cutis, Editorial Advisory Board, Quadrant Healthcom, Inc.
2001 – Present
Cosmetic Dermatology, Senior Editor, Quadrant Healthcom, Inc.
2001 – 2004
Triple I Podiatry Prescribing Guide, Editorial Advisory Board,
MediMedia USA, Inc.
2001 – 2004
Pathways to Clinical Practice, Editor, Quarterly Newsletter,
HMP Publications, Inc.
2003 – Present
Journal of Drugs in Dermatology, International Editorial Board,
Strategic Communication in Dermatology, Inc.
Publications
Werschler, WP. Total Intravenous Anesthesia for Office-Based Laser Facial
Resurfacing. Lasers in Surgery and Medicine; Supplemental 9, 1997:34.
Werschler, WP., et al. Cosmetic Office Practice – A Novel Perspective. Progressive
Clinical Insights, January/February 1998; Vol. 6(1): 24-25.
Werschler, WP. Why the Time is Now to Promote Cosmetic Prodecures. Sking &
Aging, April 1998; Vol. 6(4): 32-33.
Werschler, WP. How You Can Integrate Cosmetic Procedures Into Your Practice. Skin
& Aging, May 1998; Vol. 6(5): 41-43.
Werschler, WP. Overcome the Challenges of Adding Laser Procedures to Your Practice.
Skin & Aging, July 1998; Vol. 6(7): 59-62.
Werschler, WP. Making Mid-level Providers Work for You. Skin & Aging, February
1999; Vol. 7(2): 53-57.
Werschler, WP., et al. Emollients: Current Uses and Future Trends. Skin & Aging, June
1999 Supp.; Vol. 7(6).
Werschler, WP. What to Do When the HMO Says “No!” Skin & Aging, August 1999;
Vol. 7(8): 46-49.
Werschler, WP. The Promise and Pitfalls of Private Practice. Skin & Aging, January
2000 Supp.; Vol. 8(1): 4-7.
Werschler, WP. Wake Up Your Practice with These 13 Tips. Skin & Aging, February
2000; Vol. 8(2): 58-62.
Werschler, WP. How to Introduce Liposuction into Your Practice. Skin & Aging, April
2000; Vol. 8(4): 39-45.
Werschler, WP., et al. Rethinking Onychomycosis. Skin & Aging, July 2000 Supp.;
Vol. 8(7).
Werschler, WP. Botox: Inject New Life Into Your Practice. Skin & Aging, August
2000 Supp.; Vol 8(8)
Werschler, WP. Eczema and Contact Dermatitis. American Journal of Medicine and
Sports, 2000; Vol. 2(3): 178-181, 202.
Werschler, WP with Craze, MG. How to Develop, Manage & Market a Cosmetic
Practice, Text Book. PPMS, Spokane, WA.
Werschler, WP., Bondar, GL, Smith, SS. Occupational Risks of Malignant Melanoma.
Clinics in Occupational and Environmental Medicine, February 2001: 75-84.
Werschler, WP. What You Need to Know About the Fickleness of Cash Flow. Skin &
Aging, April 2001; Vol. 9(4): 27-28.
Werschler, WP. Economic Forecasting For Practice Development. Skin & Aging, May
2001; Vol. 9(5): 21-22.
Werschler, WP. Advice of Dispensing Prescription Pharmaceuticals. Skin & Aging,
June 2001; Vol. 9(6): 22-24.
Werschler, WP. How to Identify Problems With Your Practice. Skin & Aging,
September 2001; Vol. 9(9): 91-93.
Werschler, WP., Baumann, Leslie. Everything You Need To Know About Botox
Injection. Skin & Aging, October 2001; Vol 9(10): 36-42.
Werschler, WP. Mechanism of Drug Action Important to Consider. Dermatology Times,
November 2001; Vol. 22 Supp. 5: S8-S9.
Werschler, WP., et al. Introducing a New Service in the Dermatology Practice. Skin &
Aging, January 2002; Vol. 10(1): 43-47.
Werschler, WP., et al. Treatment of Onychomycosis in the Elderly. Clinical Geriatrics,
April 2002; Vol 10(4): 19-29.
Werschler, WP. Mixed Infection and Urticarial Drug Reaction Following CO2
Laser/TCA Peel. Cosmetic Dermatology, August 2002; Vol. 15(8): 21-22.
Werschler, WP. 10 Questions to Ask if You are Thinking About Receiving Botox
Cosmetic Therapy. Healthy Skin & Hair Summer, 2002: 7.
Werschler, WP. A New Era of Actinic Keratosis Treatment. Skin & Aging, September
2002; Vol. 10(9): 1-15.
Werschler, WP., et. al (Roundtable Participants). Clinical Dialogues: Actinic Keratosis
and Other Nonmelanoma Skin Cancers. A Supplement to Skin & Allergy News, 2004.
Werschler, WP., et. al. Assessing Treatment Outcomes in Toenail Onychomycosis
Clinical Trials. American Journal of Clinical Dermatology, 2004; 5 (3): 145-152.
Carruthers, Jean, M.D., Fagien, Steven, M.D., Matarasso, Seth L., M.D., Werschler, WP.,
et. al. (the Botox Consensus Group). Introduction to the Consensus Recommendations.
Supplement to Plastic and Reconstructive Surgery, November 2004; Vol 114(6): i-22S.
Jorizzo, Joseph L., M.D., Carney, Patrick S., M.D., Ko, William T., M.D., Robins, Perry,
M.D., Weinkle, Susan H., M.D., and Werschler, WP (Rountable Participants). Which
Options when: How to Maximize the Treatment Outcomes for Actinic Keratosis.
Supplement to Cutis, December 2004; Vol 74(6S): 4-25.
Werschler, WP, et. al. 6 Simple Steps to Sculptra Success. Skin & Aging, January 2005;
Vol 13(1): 56-59.
Werschler, WP, and Weinkle, Susan, M.D.. Longevity of Effects of Injectable Products
for Soft Tissue Augmentation. Drugs in Dermatology, January 2005: New Methods and
Techniques; Vol 4(1): 20-27.
Werschler, WP. Advances in Recognizing and Treating Facial Lipatrophy. A
Supplement to Cosmetic Dermatology, February 2005; Vol 18(2 S2): 1-4.
Werschler, WP and Harland, Brad, C.P.A. Practice Pearls: Monitoring the Financial
Health of Your Practice. Skin & Aging, February 2005; Vol 13(2): 18-19.
Werschler, WP and Harland, Brad, C.P.A. Practice Pearls: Should You Use a CostSharing Agreement? Skin & Aging, March 2005; Vol 13(3): 31-32.
Werschler, WP and Mest, Douglas R., MD. Questions and Answers: ASCDAS 3rd
Annual Meeting – New Options in the Recognition and Treatment of Lipoatrophy With
Volume Restoration. Cosmetic Dermatology, March 2005; Vol 18(3): 235-239.
Werschler, WP (Moderator), Berson, Diane S., MD, Weinkle, Susan H., MD, Weiss,
Jonathan S., and Woodson, Johnnie M., MD. The Expanding Role of 5-FU in
Dermatology. Supplement to Dermatology Times, April 2005.
Werschler, WP and Harland, Brad, C.P.A. Practice Pearls: Avoid Employee Theft:
Implement Internal Controls. Skin & Aging, May 2005; Vol 13(5): 33-34.
Werschler, WP and Vleggaar, Danny, MD. Fillers to Sculptors: Addressing Volumentric
Restoration / New Treatment Options in Lipoatrophy. Supplement to Dermatology
Times, August 2005.
Werschler, WP, Larson, Kari, BBA, and Hardland, Brad, CPA. Practice Pearls:
Choosing the Right Paid-Leave Policy. Skin & Aging, September 2005; Vol 13 (9); 3740.
Werschler, WP, Larson, Kari, BBA, and Harland, Brad, CPA. Establishing and
Evaluating Patient Satisfaction with your Practice. Cosmetic Dermatology, October
2005; Vol 18 (10); 699-701.
Werschler, WP, Larson, Kari, BBA, and Harland, Brad, CPA. Practice Pearls: Should
you Start your own Practice or Join an Existing One? Skin & Aging, October 2005; Vol
13 (10); 33-36.
Interviews & Feature Articles
Tosk, Nadine. Summer AAD Show Features of New Wave of Treatment Approaches.
Aesthetic Buyers Guide, September/October 2004.
Gillette, Bill. Know In-Office Retailing Pros, Cons. Dermatology Times, February
2005; Vol 26(2).
Gillette, Bill. Maximize Revenue: Work Smart, Not Harder. Dermatology Times,
March 2005; Vol 26(3): 78, 82.
Jesitus, John. Innovations address total facial rejuvenation. Dermatology Times,
September 2005; Vol 26 (9): 64.
Jesitus, John. Innovations address total facial rejuvenation. Cosmetic Surgery Times,
October, 2005; Vol 8(9): 10, 17.